ClinicalTrials.gg
CompletedNCT03719612BENEFIT2Updated Jan 28, 2021Results posted

DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

A Phase 3 interventional study of DEFINITY® in Cardiac Disease, sponsored by Lantheus Medical Imaging. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 646 studies in Heart Diseases with a site in United States — 93 open to participants now, 131 under way, 5 of them phase 3. Heart Diseases · United States.

Enrollment
216th of 430
160 · median 161
Started
2018
with 26 others
Phase 3
63 of 646
2 open now
Registered
446th of 646
by date

Among the 646 studies in Heart Diseases with a site in United States, this one is the 216th largest by enrollment of the 430 interventional ones that give a count, is one of 27 that started in 2018, is one of 63 in phase 3, and was the 446th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 251 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

93 of the 646 studies in Heart Diseases with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 181 Heart Diseases studies recruiting now, 128 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 32 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 646 studies in Heart Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as compared with non-contrast cardiac magnetic resonance imaging (CMR) used as the truth standard.

03

Conditions studied

  • Cardiac Disease

Browse trials for

Keywords

  • Left Ventricular Ejection Fraction
  • DEFINITY®
  • Enhanced Echocardiogram
  • Cardiac Magnetic Resonance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥ 18 years of age in sinus rhythm
  2. Able to communicate effectively with trial personnel
  3. measurements obtained via 2D Echo with or without contrast obtained within 6 months prior to enrollment (Day 0)
  4. Has provided signed after receiving a verbal and written explanation of this clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant or lactating. All women of child bearing potential [] must have a negative urine pregnancy test at screening regardless of use history.
  2. Women of child-bearing potential are excluded unless they:

    1. are defined as amenorrhea ≥ 12 consecutive months, OR
    2. have undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy), OR
    3. have been using an adequate and medically approved method of contraception to avoid pregnancy for at least 1 month prior to DEFINITY® dose administration and be willing to continue using the same method for the duration of the study.
  3. Current illness or pathology that would prevent undergoing product administration due to a significant safety risk to the patient.
  4. Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic blood pressure ≤ 90 mmHg).
  5. Unstable cardiovascular status defined as:

    1. myocardial infarction or unstable angina pectoris within 6 months prior to enrollment/DEFINITY® dose administration day
    2. or stroke within 3 months prior to DEFINITY® dose administration
    3. symptomatic valvular heart disease or moderate to severe stenotic valvular heart disease
    4. congenital heart defects
    5. current uncontrolled cardiac arrhythmias causing symptoms or hemodynamic compromise
    6. acute pulmonary embolus or pulmonary infarction
    7. acute myocarditis or pericarditis
    8. acute aortic dissection
    9. atrial fibrillation
  6. any major surgery within 4 weeks prior to screening
  7. known to undergoing CMR (e.g. implanted pacemakers, cardioverter, defibrillators) or claustrophobia
  8. participation in any investigational drug, device, or placebo study within 30 days prior to screening
  9. known to perflutren, or any of the in DEFINITY®
  10. prisoners or those who are subject to compulsory detention or involuntary incarceration for treatment of either a psychiatric or physical illness (e.g., infectious disease).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    DEFINITY®

    Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound

    Drug: DEFINITY®

Interventions

  • All subjects will receive a single dose of DEFINITY®

06

What researchers measure

Primary outcomes

  1. Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader

    Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography by comparing LVEF percentage differences from CMR measured by 3 independent blinded image readers.

    Time frame: Up to 30 days between day of echocardiograms and CMR imaging

Secondary outcomes

  1. Secondary Objective 1: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader for Sub-optimal Echocardiograms

    Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography in subjects with suboptimal echocardiograms by comparing LVEF percentage differences from CMR measured by 3 independent blinded readers.

    Time frame: Up to 30 days between day of echocardiogram and CMR imaging

  2. Secondary Objective 2: Absolute Value LVEF Percentage Differences From CMR Between Blinded Readers

    Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF percentage differences from CMR between 3 independent blinded readers.

    Time frame: Up to 30 days between day of echocardiograms and CMR imaging

  3. Secondary Objective 3: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers

    Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers.

    Time frame: Up to 30 days between day of echocardiogram and CMR imaging

  4. Secondary Objective 4: Absolute Value of LVEF Percentage Differences From CMR Between Readers for Sub-optimal Echocardiograms

    Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF percentage differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.

    Time frame: Up to 30 days between day of echocardiograms and CMR imaging

  5. Secondary Objective 5: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms

    Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.

    Time frame: Up to 30 days between day of echocardiograms and CMR imaging

07

Results

Posted Jan 7, 2021

Participant flow

Participant flow — Overall Study
MilestoneDEFINITY®
Started160
Completed148
Not completed12

Outcome measures

PrimaryAbsolute Value of LVEF Percentage Differences From CMR by Blinded Reader

Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography by comparing LVEF percentage differences from CMR measured by 3 independent blinded image readers.

Time frame:
Up to 30 days between day of echocardiograms and CMR imaging
Reported as:
Mean · Percent Ejection Fraction
Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader
Percent Ejection FractionBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced5.70 ± 4.2925.88 ± 4.3305.03 ± 3.548
Echo Unenhanced6.08 ± 4.5306.00 ± 4.8135.36 ± 3.889
Statistical analysis
  • Blinded Reader 1 · t-test, 2 sided · p = 0.358 · Mean difference (final values): -0.38Paired t-test
  • Blinded Reader 2 · t-test, 2 sided · p = 0.804 · Mean difference (final values): -0.12Paired t-test
  • Blinded Reader 3 · t-test, 2 sided · p = 0.371 · Mean difference (final values): -0.33Paired t-test
SecondarySecondary Objective 1: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader for Sub-optimal Echocardiograms

Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography in subjects with suboptimal echocardiograms by comparing LVEF percentage differences from CMR measured by 3 independent blinded readers.

Time frame:
Up to 30 days between day of echocardiogram and CMR imaging
Reported as:
Mean · Percent Ejection Fraction
Secondary Objective 1: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader for Sub-optimal Echocardiograms
Percent Ejection FractionBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced5.67 ± 3.7176.16 ± 3.7464.68 ± 3.456
Echo Unenhanced6.95 ± 5.2196.81 ± 4.6945.33 ± 3.764
Statistical analysis
  • Blinded Reader 1 · t-test, 2 sided · p = 0.030 · Mean difference (final values): -1.28Paired t-test
  • Blinded Reader 2 · t-test, 2 sided · p = 0.312 · Mean difference (final values): -0.66Paired t-test
  • Blinded Reader 3 · t-test, 2 sided · p = 0.347 · Mean difference (final values): -0.65Paired t-test
SecondarySecondary Objective 2: Absolute Value LVEF Percentage Differences From CMR Between Blinded Readers

Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF percentage differences from CMR between 3 independent blinded readers.

Time frame:
Up to 30 days between day of echocardiograms and CMR imaging
Reported as:
Mean · Percent Ejection Fraction
Secondary Objective 2: Absolute Value LVEF Percentage Differences From CMR Between Blinded Readers
Percent Ejection FractionBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced5.70 ± 4.2925.88 ± 4.3305.03 ± 3.548
Echo Unenhanced6.08 ± 4.5306.00 ± 4.8135.36 ± 3.889
Statistical analysis
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.984 · 95% CI 0.977 to 0.988
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.953 · 95% CI 0.936 to 0.966
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.970 · 95% CI 0.958 to 0.978
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.944 · 95% CI 0.923 to 0.959
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.961 · 95% CI 0.947 to 0.972
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.942 · 95% CI 0.920 to 0.958
SecondarySecondary Objective 3: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers

Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers.

Time frame:
Up to 30 days between day of echocardiogram and CMR imaging
Reported as:
Mean · mL
Secondary Objective 3: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers
mLBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced End Diastolic57.85 ± 44.20451.13 ± 43.39147.97 ± 40.589
Echo Unenhanced End Diastolic64.91 ± 44.08462.01 ± 43.39248.32 ± 39.895
Echo Enhanced End Systolic38.05 ± 32.92132.41 ± 32.89631.68 ± 30.603
Echo Unenhanced End Systolic42.87 ± 34.79339.08 ± 34.13932.45 ± 31.314
Statistical analysis
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.984 · 95% CI 0.978 to 0.988
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.976 · 95% CI 0.967 to 0.983
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.973 · 95% CI 0.963 to 0.981
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.935 · 95% CI 0.910 to 0.952
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.973 · 95% CI 0.962 to 0.980
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.924 · 95% CI 0.896 to 0.945
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.989 · 95% CI 0.984 to 0.992
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.983 · 95% CI 0.977 to 0.988
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.984 · 95% CI 0.978 to 0.989
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.948 · 95% CI 0.928 to 0.962
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.978 · 95% CI 0.969 to 0.984
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.942 · 95% CI 0.920 to 0.958
SecondarySecondary Objective 4: Absolute Value of LVEF Percentage Differences From CMR Between Readers for Sub-optimal Echocardiograms

Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF percentage differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.

Time frame:
Up to 30 days between day of echocardiograms and CMR imaging
Reported as:
Mean · Percent Ejection Fraction
Secondary Objective 4: Absolute Value of LVEF Percentage Differences From CMR Between Readers for Sub-optimal Echocardiograms
Percent Ejection FractionBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced5.67 ± 3.7176.16 ± 3.7464.68 ± 3.456
Echo Unenhanced6.95 ± 5.2196.81 ± 4.6945.33 ± 3.764
Statistical analysis
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.975 · 95% CI 0.956 to 0.986
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.936 · 95% CI 0.888 to 0.963
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.961 · 95% CI 0.931 to 0.978
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.921 · 95% CI 0.864 to 0.955
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.947 · 95% CI 0.907 to 0.970
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.903 · 95% CI 0.834 to 0.945
SecondarySecondary Objective 5: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms

Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.

Time frame:
Up to 30 days between day of echocardiograms and CMR imaging
Reported as:
Mean · mL
Secondary Objective 5: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms
mLBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced End Diastolic71.67 ± 49.91663.73 ± 49.57161.86 ± 47.523
Echo Unenhanced End Diastolic74.89 ± 51.46869.07 ± 46.31664.38 ± 46.827
Echo Enhanced End Systolic45.59 ± 32.84438.55 ± 33.49339.52 ± 30.946
Echo Unenhanced End Systolic48.00 ± 37.63941.88 ± 32.98940.72 ± 32.333
Statistical analysis
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.984 · 95% CI 0.971 to 0.991
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.975 · 95% CI 0.956 to 0.986
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.977 · 95% CI 0.959 to 0.987
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.940 · 95% CI 0.896 to 0.966
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.977 · 95% CI 0.959 to 0.987
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.923 · 95% CI 0.866 to 0.956
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.990 · 95% CI 0.982 to 0.994
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.976 · 95% CI 0.957 to 0.986
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.985 · 95% CI 0.973 to 0.991
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.929 · 95% CI 0.876 to 0.959
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.981 · 95% CI 0.966 to 0.989
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.916 · 95% CI 0.855 to 0.952

Adverse events

Collected over Up to 12 days: Enrolled subjects were followed for adverse events and serious adverse events from the time the Informed Consent was signed at screening (Day -7 to Day 0) through 72+/-24 hours after completion of Definity administration (Day 0).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DEFINITY®0/160 (0%)1/160 (0.6%)0/160 (0%)
Most frequent serious events
Most frequent serious events
EventDEFINITY®
Small intestinal obstructionGastrointestinal disorders1/160

Baseline characteristics

Baseline data are calculated based on Safety Population

Age, Categorical
Age, Categorical(Participants)DEFINITY®
<=18 years0
Between 18 and 65 years106
>=65 years54
Sex: Female, Male
Sex: Female, Male(Participants)DEFINITY®
Female55
Male105
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DEFINITY®
Hispanic or Latino14
Not Hispanic or Latino146
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DEFINITY®
American Indian or Alaska Native1
Asian3
Native Hawaiian or Other Pacific Islander2
Black or African American32
White120
More than one race2
Unknown or Not Reported0
LVEF Group
LVEF Group(Participants)DEFINITY®
LVEF <30%45
LVEF 30-40%48
LVEF 41-50%27
LVEF >50%40
08

Study locations

15 sites
  • Banner University of Arizona Medical Center
    Tucson, Arizona 85724, United States
  • Cedars Sinai
    Los Angeles, California 90048, United States
  • University of California-Irvine
    Orange, California 92868, United States
  • UC San Diego
    San Diego, California 92037, United States
  • Alfieri Cardiology
    Wilmington, Delaware 19803, United States
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
  • Indiana University
    Bloomington, Indiana 46202, United States
  • Baptist Hospital
    Paducah, Kentucky 42003, United States
  • Mercy Unit Hospital
    Coon Rapids, Minnesota 55433, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health and Sciences University
    Portland, Oregon 97240, United States
  • Albert Einstein Medical Center
    Philadelphia, Pennsylvania 19412, United States
  • Baylor Scott White Research Institute
    Temple, Texas 76501, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jan 2020, 12 months.

Results were first posted in Jan 2021, 11 months after primary completion.

Of 32 phase 3 interventional studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2018
First posted
Oct 25, 2018
StartActual
Dec 28, 2018
Primary completionActual
Jan 9, 2020
CompletionActual
Jan 9, 2020
Results first posted
Jan 7, 2021
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03719612
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Oct 25, 2018
Start date
Dec 28, 2018
Primary completion
Jan 9, 2020
Completion
Jan 9, 2020
Results posted
Jan 7, 2021
Last update
Jan 28, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perflutren

Start the discussion